Recursion Pharmaceuticals (RXRX) Upgraded to Overweight by JPMorgan with $11 Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Yahoo Finance
- Investor Interest: Cathie Wood's ARK Investment purchased 755,000 shares of Recursion Pharmaceuticals (RXRX) on December 19, 2025, indicating strong confidence in the company, which may drive stock price appreciation and attract further investor interest.
- Rating Upgrade: On December 17, 2025, JPMorgan upgraded Recursion Pharmaceuticals from Neutral to Overweight with a price target raised from $10 to $11, reflecting recognition of the long-term efficacy and market potential of its familial adenomatous polyposis treatment, REC-4881.
- Market Potential: Analysts noted that REC-4881's addressable market is larger than previously anticipated, with a 60% chance of success and peak revenues expected to exceed $1 billion, providing robust support for the company's future financial performance.
- Financial Outlook: Recursion Pharmaceuticals reiterated its 2025 expense base of less than $450 million, with cash flow expected to sustain operations until the end of 2027, demonstrating strong financial management that could enhance investor confidence.
Analyst Views on RXRX
Wall Street analysts forecast RXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXRX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.130
Low
8.00
Averages
8.00
High
8.00
Current: 4.130
Low
8.00
Averages
8.00
High
8.00
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
